| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695747 | Gynecologic Oncology | 2017 | 6 Pages |
Abstract
This study is the first demonstration of an association between NY-ESO-1 expression and an aggressive cancer phenotype. The relatively high expression frequency of NY-ESO-1 in ovarian cancer patients coupled with the poor clinical outcomes in NY-ESO-1Â + patients reveals an underappreciated need for targeted therapy against this antigen. In support, our study reveals that NY-ESO-1Â + patients enrolled on immunotherapy trials targeting the antigen exhibited an improvement in OS.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
J. Brian Szender, Antonios Papanicolau-Sengos, Kevin H. Eng, Anthony J. Miliotto, Amit A. Lugade, Sacha Gnjatic, Junko Matsuzaki, Carl D. Morrison, Kunle Odunsi,